In 2010, the French-speaking Society of Diabetes (SFD; *Société Francophone du Diabète*) and French National College of Obstetricians and Gynaecologists (CNGOF) proposed an expert consensus on screening and caring for hyperglycaemia in pregnancy (HIP) in France. They recommended selective screening based on fasting plasma glucose (FPG) measurement at the time of booking, followed by a 75-g oral glucose tolerance test (OGTT) at 24--28 weeks of gestation if the initial FPG result was normal. Gestational diabetes mellitus (GDM) and diabetes in pregnancy (DIP) were both defined according to International Association of Diabetes and Pregnancy Study Groups (IADPSG)/World Health Organization (WHO) criteria ([Fig. 1](#fig0005){ref-type="fig"} A) [@bib0030].Fig. 1French-speaking Society of Diabetes (SFD) recommendations for screening for hyperglycaemia in pregnancy before and during the COVID-19 pandemic: (A) current recommendations; and (B) alternative proposed during the pandemic. Plasma glucose values: 5.1 mmol/L = 92 mg/dL; 7.0 mmol/L = 126 mg/dL; 8.5 mmol/L = 153 mg/dL; 10.0 mmol/L = 180 mg/dL; HbA~1c~: 5.7% = 39 mmol/mol; 6.5% = 48 mmol/mol. FPG: fasting plasma glucose; G1 h/G2 h: plasma glucose at 1 h/2 h after 75-g oral glucose tolerance test; GDM: gestational diabetes mellitus; HbA~1c~: glycated haemoglobin; WG: weeks of gestation.

In France, to maintain social distancing and self-isolation during the COVID-19 pandemic, some pathology collection centres have decided not to accommodate patients for the 2-h period required to perform an OGTT. In addition, some women do not wish to undergo the test. However, this decision is highly dependent on the region and hospital and/or on city structure. Nevertheless, the challenge has been to minimize the risks of COVID-19 infection and HIP-related complications. Given the latter situation, screening is still necessary and, therefore, the present authors have considered this issue on behalf of the SFD and CNGOF.

In the context of the COVID-19 pandemic, there is a need to:•limit the number of screening tests for HIP;•find alternate ways to screen for HIP when it appears to be neither sustainable nor safe to perform an OGTT.

Considering the first point, a recent French observational study found that selective screening was able to identify 84.6% of the women with HIP and also that women with HIP, but no risk factors, had a good prognosis [@bib0035]. Thus, selective screening is still recommended.

Screening tests are chosen for their high sensitivity, which may nonetheless be associated with low specificity and a high number of false-positive results. Any alternative to OGTT should minimize the possibility of missed HIP cases, particularly in women at high risk of complications. However, no single test can replace the OGTT in diagnosing GDM. The Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study showed that 50% of GDM cases, according to IADPSG criteria, were based on plasma glucose measurements at 1 h and/or 2 h after OGTT when FPG levels were normal [@bib0040]. Thus, FPG measurement alone does not appear to be sensitive enough.

The sensitivity of HbA~1c~ levels at 24--28 weeks of gestation is low for detecting HIP, as defined by IADPSG criteria: it is only 5% for HbA~1c~ ≥ 5.7% (39 mmol/mol) and 9% for HbA~1c~ ≥ 5.9% (41 mmol/mol) [@bib0045]. The Royal College of Obstetricians and Gynaecologists recently reported unpublished data from two studies ([http://2020-04-09-guidance-for-maternal-medicine-services-in-the-evolving-coronavirus-covid-19-pandemic.pdf](http://2020-04-09-guidance-for-maternal-medicine-services-in-the-evolving-coronavirus-covid-19-pandemic.pdf/){#intr0005}) of the performance of HbA~1c~ alone or in combination with FPG measurement to diagnose HIP. In a meta-analysis of 17 studies, a second/third trimester HbA~1c~ cut-off value of ≥ 5.7% (39 mmol/mol) had high specificity \[0.90; 95% confidence interval (CI): 0.70--0.95\], but poor sensitivity for HIP detection (36%; 95% CI: 23--52). Therefore, HbA~1c~ measurement alone is not sufficient.

In addition, a combined approach using both HbA~1c~ and FPG measurement was evaluated in the Pregnancy and Infant Development (PRIDE) Study cohort (4303 women): HbA~1c~ levels ≥ 5.7% (39 mmol/mol) and/or FPG levels ≥ 92 mg/dL had a detection rate of 51% for HIP, as defined by UK National Institute for Health and Care Excellence (NICE) criteria, and a 12% rate of false-positive cases. Moreover, HbA~1c~ levels have been reported to be significantly associated with adverse pregnancy outcomes, including large-for-gestational-age (LGA) infants [@bib0050], caesarean sections [@bib0050], hypertensive disorders in pregnancy [@bib0050], preterm delivery [@bib0045], neonatal hyperbilirubinaemia [@bib0045] and neonatal asphyxia [@bib0045]. Thus, a high HbA~1c~ level can identify those women who are at highest risk of adverse events.

Considering these data, we recommend the following pragmatic approach ([Fig. 1](#fig0005){ref-type="fig"}B):•at the time of booking, continue selective screening with FPG measurement;•at 24--28 weeks of gestation, if FPG levels were \< 92 mg/dL during early pregnancy, then it may be necessary to consider both FPG and HbA~1c~ values as an alternative to OGTT \[women with FPG ≥ 126 mg/dL or HbA~1c~ ≥ 6.5% (48 mmol/mol) should be considered as having DIP; women with either FPG at 92--125 mg/dL or HbA~1c~ of 5.7--6.4% should be considered as having GDM; and women with FPG \< 92 mg/dL and HbA~1c~  \< 5.7% (39 mmol/mol) should be considered normal\];•in addition, at any time during pregnancy, women with high clinical suspicion of diabetes, LGA fetuses or polyhydramnios on ultrasound should also be tested.

Where permitted by local organizations and when there are no specific challenges for either patients or laboratories, it is recommended to continue the usual routine screening ([Fig. 1](#fig0005){ref-type="fig"}A). However, in the absence of additional evidence, we recommend that this guidance be followed only for the duration of the COVID-19 pandemic, with a return back to the usual French recommended screening procedure when it appears to be safe and feasible to do so.
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